1
|
Franciosini G, Carlotti D, Cattani F, De Gregorio A, De Liso V, De Rosa F, Di Francesco M, Di Martino F, Felici G, Pensavalle JH, Leonardi MC, Marafini M, Muscato A, Paiar F, Patera V, Poortmans P, Sciubba A, Schiavi A, Toppi M, Traini G, Trigilio A, Sarti A. IOeRT conventional and FLASH treatment planning system implementation exploiting fast GPU Monte Carlo: The case of breast cancer. Phys Med 2024; 121:103346. [PMID: 38608421 DOI: 10.1016/j.ejmp.2024.103346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 03/13/2024] [Accepted: 04/01/2024] [Indexed: 04/14/2024] Open
Abstract
Partial breast irradiation for the treatment of early-stage breast cancer patients can be performed by means of Intra Operative electron Radiation Therapy (IOeRT). One of the main limitations of this technique is the absence of a treatment planning system (TPS) that could greatly help in ensuring a proper coverage of the target volume during irradiation. An IOeRT TPS has been developed using a fast Monte Carlo (MC) and an ultrasound imaging system to provide the best irradiation strategy (electron beam energy, applicator position and bevel angle) and to facilitate the optimisation of dose prescription and delivery to the target volume while maximising the organs at risk sparing. The study has been performed in silico, exploiting MC simulations of a breast cancer treatment. Ultrasound-based input has been used to compute the absorbed dose maps in different irradiation strategies and a quantitative comparison between the different options was carried out using Dose Volume Histograms. The system was capable of exploring different beam energies and applicator positions in few minutes, identifying the best strategy with an overall computation time that was found to be completely compatible with clinical implementation. The systematic uncertainty related to tissue deformation during treatment delivery with respect to imaging acquisition was taken into account. The potential and feasibility of a GPU based full MC TPS implementation of IOeRT breast cancer treatments has been demonstrated in-silico. This long awaited tool will greatly improve the treatment safety and efficacy, overcoming the limits identified within the clinical trials carried out so far.
Collapse
Affiliation(s)
- G Franciosini
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy
| | - D Carlotti
- Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitatio Campus-Bio Medico, Rome, Italy
| | - F Cattani
- Unit of Medical Physics, European Institute of Oncology IRCCS, Milan, Italy
| | - A De Gregorio
- National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy; Sapienza, University of Rome, Department of Physics, Rome, Italy
| | - V De Liso
- S.I.T. Sordina IORT Technologies S.p.A, Aprilia, Italy
| | - F De Rosa
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy
| | | | - F Di Martino
- Centro Pisano Multidisciplinare sulla Ricerca e Implementazione Clinica della Flash Radiotherapy (CPFR), Pisa, Italy; University of Pisa, Department of Physics, Pisa, Italy; Azienda Ospedaliero Universitaria Pisa (AOUP), Fisica Sanitaria, Pisa, Italy; National Institute of Nuclear Physics, INFN, Section of Pisa, Pisa, Italy
| | - G Felici
- S.I.T. Sordina IORT Technologies S.p.A, Aprilia, Italy
| | - J Harold Pensavalle
- S.I.T. Sordina IORT Technologies S.p.A, Aprilia, Italy; Centro Pisano Multidisciplinare sulla Ricerca e Implementazione Clinica della Flash Radiotherapy (CPFR), Pisa, Italy; National Institute of Nuclear Physics, INFN, Section of Pisa, Pisa, Italy
| | - M C Leonardi
- Division of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy
| | - M Marafini
- National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy; Museo Storico della Fisica e Centro Studi e Ricerche "E. Fermi", Rome, Italy
| | - A Muscato
- National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy; Specialty School of Medical Physics, La Sapienza University of Rome, Rome, Italy
| | - F Paiar
- Centro Pisano Multidisciplinare sulla Ricerca e Implementazione Clinica della Flash Radiotherapy (CPFR), Pisa, Italy; Azienda Ospedaliero Universitaria Pisa (AOUP), Fisica Sanitaria, Pisa, Italy
| | - V Patera
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy
| | - P Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
| | - A Sciubba
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Frascati National Laboratories (LNF), Rome, Italy
| | - A Schiavi
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy
| | - M Toppi
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy
| | - G Traini
- National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy
| | - A Trigilio
- Sapienza, University of Rome, Department of Physics, Rome, Italy; National Institute of Nuclear Physics, INFN, Frascati National Laboratories (LNF), Rome, Italy
| | - A Sarti
- Sapienza, University of Rome, Department of Scienze di Base e Applicate all'Ingegneria, Rome, Italy; National Institute of Nuclear Physics, INFN, Section of Rome I, Rome, Italy.
| |
Collapse
|
2
|
Carlotti D, Muscato A, De Gregorio A, de Simoni M, Fiore M, Franciosini G, Insero T, Marafini M, Marè V, Mirabelli R, Palumbo L, Ramella S, Sarti A, Schiavi A, Toppi M, Traini G, Trigilio A, Patera V. New Advantage in Stereotactic Treatment of Lung and Pancreatic Cancer. Performance of Ultra-High Energy Electron (VHEE) Therapy Adjuvanted to the FLASH Effect: Clinical Implications and Treatment Plans Analysis. Int J Radiat Oncol Biol Phys 2023; 117:e648-e649. [PMID: 37785927 DOI: 10.1016/j.ijrobp.2023.06.2068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Very High-Energy Electron (VHEE) beams delivered at ultra-high dose rates and hence profiting from the FLASH effect, may be a viable alternative to conventional treatment plans for the treatment of deep-seated tumors. Experimental data support the evidence of a considerable normal tissue sparing effect when treatments are delivered with dose rates much larger (100 times or more) compared to the conventional ones. Lung cancer and pancreatic cancer are considered the two biggest cancer killers. We urgently need more research in these areas, more awareness that support improvement in treatment strategies. To evaluate the potential of FLASH VHEE irradiation in these two clinical situations, we investigated the achievable sparing of healthy tissues and critical dose-limiting structures, with the goal of performing a higher dose prescription. MATERIALS/METHODS The study on the potential of VHEE for the stereotactic treatment of pancreatic and lung lesions was carried out on two clinical cases treated with Volumetric Modulated Arc Therapy (VMAT) techniques at University Hospital Campus Bio-Medico of Rome. The Planning Target Volume (PTV) was identified and the constraints on the Organs at Risk (OAR) and details on the irradiation approach were defined. The VHEE plan was designed to optimize the dose delivery to best activate the modelled FLASH effect based on the current experimental knowledge. In particular the impact on a dose threshold to activate the effect was studied. The VHEE treatment plan was based on an accurate Monte Carlo simulation of the electrons interactions and the results achievable with different FLASH effect models were studied. The simulation allowed the estimation of dose maps, which were used as input to an optimization algorithm that modified the fluence of each beam to meet treatment prescriptions in terms of dose to PTV. At the end the VHEE DVH plans were compared to VMAT plans. RESULTS The results demonstrated that FLASH therapy with VHEE beams of 70-130 MeV, could represent a promising alternative to standard radiotherapy allowing a comparable sparing of the healthy tissues. In the case of pancreatic cancer, the Dose Volume Histograms (DVH) showed how such a technique can be effective in sparing the duodenum. In case of lung cancers, the result showed how pulmonary tissue sparing can lead to a substantial reduction of pulmonary toxicity in comparison with the VMAT technique. CONCLUSION In the case of pancreatic cancer and assuming a non-negligible contribution from the FLASH effect, the DVH showed how the duodenum healthy tissue sparing could allow a higher dose to be prescribed at the target while keeping the constraints respected, improving the therapeutic ratio. In the case of lung cancer, the advantages of the technique are additionally increased by the significant benefit that could be related to the treatment delivery time reduction (<1s) and to the corresponding advantage coming from a reduced organ movement that translates in a lower risk of lung toxicity.
Collapse
Affiliation(s)
- D Carlotti
- Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Dipartimento di Fisica, Sapienza Università di Roma, Rome, Italy
| | - A Muscato
- Scuola Post-Laurea in Fisica Medica, Dipartimento di Scienze e Biotecnologie Medico-Chirurgiche, Sapienza Università di Roma, Rome, Italy
| | - A De Gregorio
- Dipartimento di Fisica, Sapienza Università di Roma, Rome, Italy; INFN Sezione di Roma I, Rome, Italy
| | - M de Simoni
- INFN Sezione di Roma I, Rome, Italy; Departement of Medical Physics Ludwig Maximilians Universitat Munchen (LMU), Munich, Germany
| | - M Fiore
- Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy
| | | | - T Insero
- Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
| | - M Marafini
- INFN Sezione di Roma I, Rome, Italy; Museo Storico della Fisica e Centro Studi e Ricerche "E. Fermi", Rome, Italy
| | - V Marè
- Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
| | - R Mirabelli
- INFN Sezione di Roma I, Rome, Italy; Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Rome, Italy
| | - L Palumbo
- INFN Sezione di Roma I, Rome, Italy; Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Rome, Italy
| | - S Ramella
- Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy
| | - A Sarti
- Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Rome, Italy
| | - A Schiavi
- INFN Sezione di Roma I, Rome, Italy; Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Rome, Italy
| | - M Toppi
- INFN Sezione di Roma I, Rome, Italy
| | - G Traini
- INFN Sezione di Roma I, Rome, Italy
| | - A Trigilio
- Dipartimento di Fisica, Sapienza Università di Roma, Rome, Italy; INFN Sezione di Roma I, Rome, Italy
| | - V Patera
- Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Rome, Italy
| |
Collapse
|
3
|
Franciosini G, Battistoni G, Cerqua A, De Gregorio A, De Maria P, De Simoni M, Dong Y, Fischetti M, Marafini M, Mirabelli R, Muscato A, Patera V, Salvati F, Sarti A, Sciubba A, Toppi M, Traini G, Trigilio A, Schiavi A. GPU-accelerated Monte Carlo simulation of electron and photon interactions for radiotherapy applications. Phys Med Biol 2023; 68. [PMID: 36356308 DOI: 10.1088/1361-6560/aca1f2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 11/10/2022] [Indexed: 11/12/2022]
Abstract
Objective. The Monte Carlo simulation software is a valuable tool in radiation therapy, in particular to achieve the needed accuracy in the dose evaluation for the treatment plans optimisation. The current challenge in this field is the time reduction to open the way to many clinical applications for which the computational time is an issue. In this manuscript we present an innovative GPU-accelerated Monte Carlo software for dose valuation in electron and photon based radiotherapy, developed as an update of the FRED (Fast paRticle thErapy Dose evaluator) software.Approach. The code transports particles through a 3D voxel grid, while scoring their energy deposition along their trajectory. The models of electromagnetic interactions in the energy region between 1 MeV-1 GeV available in literature have been implemented to efficiently run on GPUs, allowing to combine a fast tracking while keeping high accuracy in dose assessment. The FRED software has been bench-marked against state-of-art full MC (FLUKA, GEANT4) in the realm of two different radiotherapy applications: Intra-Operative Radio Therapy and Very High Electron Energy radiotherapy applications.Results. The single pencil beam dose-depth profiles in water as well as the dose map computed on non-homogeneous phantom agree with full-MCs at 2% level, observing a gain in processing time from 200 to 5000.Significance. Such performance allows for computing a plan with electron beams in few minutes with an accuracy of ∼%, demonstrating the FRED potential to be adopted for fast plan re-calculation in photon or electron radiotherapy applications.
Collapse
Affiliation(s)
- G Franciosini
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
| | - G Battistoni
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Milano, Italy
| | - A Cerqua
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - A De Gregorio
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
| | - P De Maria
- Scuola post-laurea in Fisica Medica, Dipartimento di Scienze e Biotecnologie medico-chirurgiche, Sapienza Universitá di Roma, Roma, Italy
| | - M De Simoni
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
| | - Y Dong
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Milano, Italy
| | - M Fischetti
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - M Marafini
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Museo Storico della Fisica e Centro Studi e Ricerche 'E. Fermi', Roma, Italy
| | - R Mirabelli
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
| | - A Muscato
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Scuola post-laurea in Fisica Medica, Dipartimento di Scienze e Biotecnologie medico-chirurgiche, Sapienza Universitá di Roma, Roma, Italy
| | - V Patera
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - F Salvati
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - A Sarti
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - A Sciubba
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy.,Istituto Nazionale di Fisica Nucleare (INFN)- Laboratori Nazionali di Frascati, Frascati, Italy
| | - M Toppi
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - G Traini
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy
| | - A Trigilio
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
| | - A Schiavi
- Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Roma, Italy.,Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| |
Collapse
|
4
|
Faillace L, Alesini D, Bisogni G, Bosco F, Carillo M, Cirrone P, Cuttone G, De Arcangelis D, De Gregorio A, Di Martino F, Favaudon V, Ficcadenti L, Francescone D, Franciosini G, Gallo A, Heinrich S, Migliorati M, Mostacci A, Palumbo L, Patera V, Patriarca A, Pensavalle J, Perondi F, Remetti R, Sarti A, Spataro B, Torrisi G, Vannozzi A, Giuliano L. Perspectives in linear accelerator for FLASH VHEE: Study of a compact C-band system. Phys Med 2022; 104:149-159. [PMID: 36427487 DOI: 10.1016/j.ejmp.2022.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 10/10/2022] [Accepted: 10/23/2022] [Indexed: 11/24/2022] Open
Abstract
PURPOSE In order to translate the FLASH effect in clinical use and to treat deep tumors, Very High Electron Energy irradiations could represent a valid technique. Here, we address the main issues in the design of a VHEE FLASH machine. We present preliminary results for a compact C-band system aiming to reach a high accelerating gradient and high current necessary to deliver a Ultra High Dose Rate with a beam pulse duration of 3μs. METHODS The proposed system is composed by low energy high current injector linac followed by a high acceleration gradient structure able to reach 60-160 MeV energy range. To obtain the maximum energy, an energy pulse compressor options is considered. CST code was used to define the specifications RF parameters of the linac. To optimize the accelerated current and therefore the delivered dose, beam dynamics simulations was performed using TSTEP and ASTRA codes. RESULTS The VHEE parameters Linac suitable to satisfy FLASH criteria were simulated. Preliminary results allow to obtain a maximum energy of 160 MeV, with a peak current of 200 mA, which corresponds to a charge of 600 nC. CONCLUSIONS A promising preliminary design of VHEE linac for FLASH RT has been performed. Supplementary studies are on going to complete the characterization of the machine and to manufacture and test the RF prototypes.
Collapse
Affiliation(s)
- L Faillace
- INFN Laboratori Nazionali di Frascati, Italy.
| | - D Alesini
- INFN Laboratori Nazionali di Frascati, Italy
| | - G Bisogni
- INFN Sezione di Pisa, Italy; Department of Physics, University of Pisa, 56127 Pisa, Italy
| | - F Bosco
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - M Carillo
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - P Cirrone
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - G Cuttone
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - D De Arcangelis
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - A De Gregorio
- INFN Sezione di Roma, Italy; Department of Physics, Sapienza University, Piazzale Aldo Moro 2, 00185 Rome, Italy
| | - F Di Martino
- U.O. Fisica Sanitaria, Azienda Universitaria Ospedaliera Pisana, Pisa, Italy
| | - V Favaudon
- Institut Curie, Paris-Saclay University, PSL Research University, INSERM U1021/UMR3347, Orsay, France
| | - L Ficcadenti
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - D Francescone
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - G Franciosini
- INFN Sezione di Roma, Italy; Department of Physics, Sapienza University, Piazzale Aldo Moro 2, 00185 Rome, Italy
| | - A Gallo
- INFN Laboratori Nazionali di Frascati, Italy
| | - S Heinrich
- Institut Curie, Paris-Saclay University, PSL Research University, INSERM U1021/UMR3347, Orsay, France
| | - M Migliorati
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - A Mostacci
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - L Palumbo
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - V Patera
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - A Patriarca
- Institut Curie, PSL Research University, Proton Therapy Centre, Centre Universitaire, Orsay, France
| | - J Pensavalle
- INFN Sezione di Pisa, Italy; Department of Physics, University of Pisa, 56127 Pisa, Italy
| | - F Perondi
- SBAI Department, Sapienza University of Rome, Italy
| | - R Remetti
- SBAI Department, Sapienza University of Rome, Italy
| | - A Sarti
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| | - B Spataro
- INFN Laboratori Nazionali di Frascati, Italy
| | - G Torrisi
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - A Vannozzi
- INFN Laboratori Nazionali di Frascati, Italy
| | - L Giuliano
- SBAI Department, Sapienza University of Rome, Italy; INFN Sezione di Roma, Italy
| |
Collapse
|
5
|
Porrazzo A, Cipressa F, De Gregorio A, De Pittà C, Sales G, Ciapponi L, Morciano P, Esposito G, Tabocchini MA, Cenci G. Author Correction: Low dose rate γ-irradiation protects fruit fly chromosomes from double strand breaks and telomere fusions by reducing the esi-RNA biogenesis factor Loquacious. Commun Biol 2022; 5:1033. [PMID: 36175493 PMCID: PMC9522893 DOI: 10.1038/s42003-022-03984-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- A Porrazzo
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy.,Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy
| | - F Cipressa
- Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy.,Centro Studi e Ricerche "Enrico Fermi", Rome, Italy.,Department of Ecological and Biological Sciences, Università degli Studi della Tuscia, Viterbo, Italy
| | - A De Gregorio
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy
| | - C De Pittà
- Dipartimento di Biologia, Università di Padova, Padua, Italy
| | - G Sales
- Dipartimento di Biologia, Università di Padova, Padua, Italy
| | - L Ciapponi
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy
| | - P Morciano
- INFN-Laboratori Nazionali del Gran Sasso, 67100, Assergi, Italy
| | - G Esposito
- Istituto Superiore di Sanita' ISS, Rome, Italy.,INFN-Roma 1, Rome, Italy
| | | | - G Cenci
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy. .,Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy.
| |
Collapse
|
6
|
Porrazzo A, Cipressa F, De Gregorio A, De Pittà C, Sales G, Ciapponi L, Morciano P, Esposito G, Tabocchini MA, Cenci G. Low dose rate γ-irradiation protects fruit fly chromosomes from double strand breaks and telomere fusions by reducing the esi-RNA biogenesis factor Loquacious. Commun Biol 2022; 5:905. [PMID: 36057690 PMCID: PMC9440893 DOI: 10.1038/s42003-022-03885-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 08/23/2022] [Indexed: 12/03/2022] Open
Abstract
It is still continuously debated whether the low-dose/dose-rate (LDR) of ionizing radiation represents a hazard for humans. Model organisms, such as fruit flies, are considered valuable systems to reveal insights into this issue. We found that, in wild-type Drosophila melanogaster larval neuroblasts, the frequency of Chromosome Breaks (CBs), induced by acute γ-irradiation, is considerably reduced when flies are previously exposed to a protracted dose of 0.4 Gy delivered at a dose rate of 2.5 mGy/h. This indicates that this exposure, which is associated with an increased expression of DNA damage response proteins, induces a radioadaptive response (RAR) that protects Drosophila from extensive DNA damage. Interestingly, the same exposure reduces the frequency of telomere fusions (TFs) from Drosophila telomere capping mutants suggesting that the LDR can generally promote a protective response on chromatin sites that are recognized as DNA breaks. Deep RNA sequencing revealed that RAR is associated with a reduced expression of Loquacious D (Loqs-RD) gene that encodes a well-conserved dsRNA binding protein required for esiRNAs biogenesis. Remarkably, loss of Loqs mimics the LDR-mediated chromosome protection as it decreases the IR-induced CBs and TFs frequency. Thus, our molecular characterization of RAR identifies Loqs as a key factor in the cellular response to LDR and in the epigenetic routes involved in radioresistance. Chronic low y-radiation exposure to Drosophila cells decreases chromosome breaks induced by high-dose irradiation and telomere dysfunction by reducing the esiRNA biogenesis factor Loquacious D.
Collapse
Affiliation(s)
- A Porrazzo
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy.,Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy
| | - F Cipressa
- Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy.,Centro Studi e Ricerche "Enrico Fermi", Rome, Italy
| | - A De Gregorio
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy
| | - C De Pittà
- Dipartimento di Biologia, Università di Padova, Padua, Italy
| | - G Sales
- Dipartimento di Biologia, Università di Padova, Padua, Italy
| | - L Ciapponi
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy
| | - P Morciano
- INFN-Laboratori Nazionali del Gran Sasso, 67100, Assergi, Italy
| | - G Esposito
- Istituto Superiore di Sanita' ISS, Rome, Italy.,INFN-Roma 1, Rome, Italy
| | | | - G Cenci
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza Università di Roma, Rome, Italy. .,Fondazione Cenci Bolognetti/ Istituto Pasteur Italia, Rome, Italy.
| |
Collapse
|
7
|
De Simoni M, Baroni G, Battistoni G, Bisogni M, Cerello P, Ciocca M, Donetti M, Dong Y, Embriaco A, Ferrero V, Fiorina E, Fischetti M, Franciosini G, Giacchi G, Kraan A, Luongo C, Maggi M, Mancini Terracciano C, Marafini M, Malekzadeh E, Mattei I, Mazzoni E, Mirandola A, Morrocchi M, Muraro S, Patera V, Pennazio F, Schiavi A, Solfaroli-Camillucci E, Sportelli G, Tampellini S, Toppi M, Traini G, Trigilio A, Vischioni B, Vitolo V, Carlotti D, De Gregorio A, Sarti A. PD-0897 In vivo verification by detection of charged fragments in carbon ion therapy treatments at CNAO. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02976-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Trigilio A, Carlotti D, De Gregorio A, De Maria P, De Simoni M, Fischetti M, Franciosini G, Garbini M, Marafini M, Muscato A, Patera V, Schiavi A, Sciubba A, Toppi M, Traini G, Sarti A. OC-0279 FlashDC project: development of a beam monitor for FLASH therapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02537-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Toppi M, De Gregorio A, De Maria P, De Simoni M, Fischetti M, Franciosini G, Marafini M, Patera V, Schiavi A, Sciubba A, Traini G, Trigilio A, Sarti A. FLASHDC PROJECT: DEVELOPMENT OF A BEAM MONITOR FOR FLASH RADIOTHERAPY. Phys Med 2022. [DOI: 10.1016/s1120-1797(22)01625-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
10
|
Widschwendter P, Köhler M, Friedl T, Ammann B, Janni W, Rhomberg C, Karner M, Beer M, De Gregorio A, Polasik A. Diagnosis of presence and extent of deep infiltrating endometriosis by preoperative MRI-improvement of staging accuracy by expert training. J Gynecol Obstet Hum Reprod 2021; 51:102236. [PMID: 34592437 DOI: 10.1016/j.jogoh.2021.102236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 06/30/2021] [Accepted: 09/24/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION This study evaluates the clinical utility of magnetic resonance imaging (MRI) for the determination of presence and extent of DIE with special emphasis on effects of MRI reporting training MATERIAL AND METHODS: Data from 80 patients with clinically suspected DIE presented at our certified endometriosis center between 2015 and 2018 were analyzed. For all patients an ENZIAN score (describing DIE related to individual anatomical localizations) was obtained based on the preoperative MRI findings. The intraoperatively determined ENZIAN score served as the reference for assessment of diagnostic performance of the MRI. RESULTS Overall, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of DIE by MRI were 76.9%, 53.3%, 87.7% and 34.8%, respectively. Analysis by compartment revealed a sensitivity, specificity, PPV and NPV of 59.5%, 88.2%, 86.2% and 63.9%, respectively, for compartment A, with similar values for compartment B, and 50.0%, 88.9%, 64.7% and 81.4%, respectively, for the less often affected compartment C. Expert training (n = 32 before, n = 48 after) led to a considerable increase in sensitivities for the overall detection of DIE (84.6% vs. 65.4%, p = 0.071) and for the detection of DIE in compartment A (71.4% vs. 35.7%, p = 0.026), compartment B (66.7% vs. 37.5%, p = 0.057) and compartment C (75.0% vs. 20.0%, p = 0.010), without significant loss in specificity (all p > 0.50). DISCUSSION After expert training, MRI has a good sensitivity with fair specificity regarding preoperative assessment of presence, location and extent of DIE.
Collapse
Affiliation(s)
- P Widschwendter
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany; Department of Gynecology and Obstetrics, General Hospital Hall, Milserstrasse 10, 6060 Hall in Tirol, Austria
| | - M Köhler
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany
| | - Twp Friedl
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany
| | - B Ammann
- Department of Radiology, University Hospital Ulm, Albert Einstein Allee 23, 89081 Ulm, Germany
| | - W Janni
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany
| | - C Rhomberg
- Department of Gynecology and Obstetrics, General Hospital Hall, Milserstrasse 10, 6060 Hall in Tirol, Austria
| | - M Karner
- Department of Radiology, General Hospital Bruneck, Spitalstraße 11, 39031 Bruneck, Italy
| | - M Beer
- Department of Radiology, University Hospital Ulm, Albert Einstein Allee 23, 89081 Ulm, Germany
| | - A De Gregorio
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany
| | - A Polasik
- Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075 Ulm, Germany.
| |
Collapse
|
11
|
Polasik A, De Gregorio A, Fritz J, De Gregorio N, Janni W, Bauer E. Der seltene Fall eines ulzerierenden Hidradenoms der Vulva. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Polasik
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| | - A De Gregorio
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| | - J Fritz
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| | - N De Gregorio
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| | - W Janni
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| | - E Bauer
- Universitätsklinikum Ulm, Gynäkologie und Geburtshilfe
| |
Collapse
|
12
|
Fink A, Braun T, Heitmeir B, Bartholomä S, De Gregorio A, Janni W, De Gregorio N. 12-jähriges Mädchen mit FIGO IIIa Ovarialkarzinom – Eine extrem seltene Tumorerkrankung. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | - S Bartholomä
- Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Ulm
| | | | | | | |
Collapse
|
13
|
Braun T, Baumann L, Rack B, Fritz J, Fink A, Koretz K, Fink V, Huober J, Janni W, De Gregorio A, De Gregorio N. Myofibroblastom der Brust – eine differentialdiagnostische Herausforderung. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- T Braun
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - L Baumann
- Universitätsklinikum Ulm, Institut für Pathologie
| | - B Rack
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - J Fritz
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - A Fink
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - K Koretz
- Universitätsklinikum Ulm, Institut für Pathologie
| | - V Fink
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - J Huober
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - W Janni
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - A De Gregorio
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| | - N De Gregorio
- Universitätsklinikum Ulm, Klinik Für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
14
|
Widschwendter P, Janni W, Scholz C, De Gregorio A, De Gregorio N, Friedl TWP. Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer. Arch Gynecol Obstet 2019; 300:1709-1718. [PMID: 31696367 DOI: 10.1007/s00404-019-05341-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Accepted: 10/15/2019] [Indexed: 01/12/2023]
Abstract
PURPOSE Lymph node metastases significantly worsen the prognosis in cervical carcinoma. Risk factors-pathological and patient related-could select patients at high risk for lymph node involvement. METHODS This retrospective analysis was performed by analyzing data from patients with cervical carcinoma treated between 2000 and 2017 at the Department of Obstetrics and Gynecology of the University Hospital Ulm. RESULTS In total, 261 patients with cervical carcinoma (International Federation of Gynecology and Obstetrics (FIGO) stage IA-IIB) and lymphadenectomy with at least 10 removed lymph nodes were available for analysis. Overall, 86 (33.0%) patients had lymph node metastases; 73 patients had pelvic lymph node metastases only and 13 patients had both pelvic and paraaortic lymph node metastases. Lymph node metastases were found most often in the region of the external iliac artery and obturator fossa, with 57.0% and 54.7% of all 86 node-positive patients, respectively. Univariable analyses showed that presence of lymph node metastases was significantly associated with both preoperative FIGO stage (p = 0.001) and final pathological tumor stage (p < 0.001), status of resection margin (p = 0.002), lymphovascular space invasion (LVSI), (p < 0.001) and vascular space invasion, (p < 0.001). In a multivariable logistic regression model with presence of lymph node metastases (yes/no) as binary response variable, only LVSI (p < 0.001) and body mass index (BMI), (p = 0.035) remained as significant independent predictors of lymph node involvement. Subgroup analyses showed that LVSI was a significant predictive factor for lymph node involvement in patients with a preoperatively assessed FIGO stage < IIB (p < 0.001), but not for patients with a preoperatively assessed FIGO stage ≥ IIB (p = 0.122). CONCLUSIONS The risk factor LVSI should play an important role in deciding whether an individualized therapy concept is based on escalating or deescalating treatment. In future, the sentinel concept could reduce morbidity and at the same time provide an important prognostic assessment for a subset of cervical cancer patients.
Collapse
Affiliation(s)
- P Widschwendter
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany.
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
| | - C Scholz
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
| | - A De Gregorio
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
| | - N De Gregorio
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
| | - T W P Friedl
- Department of Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
| |
Collapse
|
15
|
Huober J, Nagel G, Rempen A, Schlicht E, Flock F, Fritz S, Thiel F, Wiesmüller L, Felderbaum R, Heilmann V, Bekes I, Fink V, Albrecht S, De Gregorio N, Tzschaschel M, Ernst K, Wolf C, Kuhn P, Friedl T, Janni W, De Gregorio A. Abstract OT1-11-01: The BRandO BiO registry – A multicenter regional registry for patients with primary breast and ovarian cancer with longitudinal biobanking and evaluation of epidemiological, life style and quality of life factors. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Further progress in the treatment of breast cancer will likely come from contributions of molecular biology and immunologic approaches. The search for druggable molecular aberrations may enable treatment based on the molecular profile. A better identification of patients with a high risk of relapse facilitates the selection of these pts for clinical trials investigating early therapeutic molecular-based interventions.
Trial Design:
The BRandO BiO Registry is a multi-center regional registry to record clinical, epidemiological, and biological data from patients with newly diagnosed breast and ovarian cancer at the University of Ulm, Dept. of Gynecology and 19 affiliated network hospitals and practices in the Alb-Allgäu Bodensee region (outreach area of the Comprehensive Cancer Center Ulm). Longitudinal biobanking is included with collection of paraffin-embedded samples of the primary tumor as well as blood samples at first diagnosis, after 6 and 12 months and at first relapse to isolate and investigate cell-free and germline DNA. Epidemiological, life style and quality of life (QOL) questionnaires are collected at first diagnosis, after 12, 36 and 60 months. The follow up is planned for 10 years.
Eligibility criteria:
Patients with primary newly diagnosed untreated breast or ovarian cancer of ≥ 18 years are eligible; primary metastatic untreated disease is allowed. Exclusion criteria comprise severe neurological or psychiatric disorders interfering with the ability to give an informed consent, no consent for registration, storage and processing of the individual disease characteristics and bio samples, and any malignant tumor in the last 3 years (except in situ disease).
Specific aims:
To register the majority of patients with newly diagnosed breast or ovarian cancer in all BRandO-BiO participating centers of a well-defined geographical area. To assess clinical characteristics and outcome data (event-free survival, overall survival) of these patients. To evaluate the primary tumor of all patients for mutational (druggable) aberrations. Further to assess cell-free DNA in the serial blood samples at baseline, 6 and 12 months and correlate these results with clinical outcome data as well as tumor and patient characteristics to look for early markers predicting relapse. To perform a longitudinal assessment of the patients' sociodemographic factors, comorbidities, lifestyle and QOL factors by analyzing serial questionnaires collected at recruitment and at 12, 36 and 60 months.
Present accrual and target accrual:
The BRandO BiO Registry started January 2016 in the Dept. of Gynecology, University of Ulm and February 2017 at the network hospitals and practices. Until June 2018, 1180 patients with primary breast or ovarian cancer have been enrolled. The current adherence to serial blood testing and serial questionnaires is good with a return rate of 90%. A sample size of 3000 patients is planned.
Contact information:
Jens Huober, University of Ulm, Dept of Gynecology, Breast Center, jens.huober@uniklinik-ulm.de
Amelie de Gregorio, University of Ulm, Dept of Gynecology, Breast Center, Amelie.de Gregorio@uniklinik-ulm.de
Citation Format: Huober J, Nagel G, Rempen A, Schlicht E, Flock F, Fritz S, Thiel F, Wiesmüller L, Felderbaum R, Heilmann V, Bekes I, Fink V, Albrecht S, De Gregorio N, Tzschaschel M, Ernst K, Wolf C, Kuhn P, Friedl T, Janni W, De Gregorio A. The BRandO BiO registry – A multicenter regional registry for patients with primary breast and ovarian cancer with longitudinal biobanking and evaluation of epidemiological, life style and quality of life factors [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-11-01.
Collapse
Affiliation(s)
- J Huober
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - G Nagel
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - A Rempen
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - E Schlicht
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - F Flock
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - S Fritz
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - F Thiel
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - L Wiesmüller
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - R Felderbaum
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - V Heilmann
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - I Bekes
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - V Fink
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - S Albrecht
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - N De Gregorio
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - M Tzschaschel
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - K Ernst
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - C Wolf
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - P Kuhn
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - T Friedl
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - W Janni
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| | - A De Gregorio
- University Hospital Ulm, Ulm, Germany; Diakonie-Hospital, Schwäbisch Hall, Schwäbisch-Hall, Germany; Staufer-Hospital, Schwäbisch Gmünd, Schwäbisch-Gmünd, Germany; Hospital Memmingen, Memmingen, Germany; Sana Clinics, Biberach, Biberach, Germany; Hospital Kempten-Oberallgäu GmbH, Kempten, Kempten, Germany; Private Practice Dr. Volkmar Heilmann, Günzburg, Günzburg, Germany; Medical Center-Dr. C. Wolf, Ulm, Ulm, Germany; Institute of Epidemiology, University Ulm, Ulm, Germany; Clinical Cancer Register, University Hospital of Ulm, Ulm, Germany; Hospital Alb-Fils, Clinic am Eichert, Alb-Fils, Göppingen, Germany
| |
Collapse
|
16
|
Krause S, Friedl T, Fehm T, Romashova T, Fasching PA, Schneeweiss A, Müller V, Taran FA, Polasik A, Tzschaschel M, De Gregorio A, Meier-Stiegen F, Janni W, Huober J. Abstract OT2-07-01: DETECT V/CHEVENDO – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Metastatic breast cancer (MBC) is usually an incurable disease and maintenance of quality of life (QoL) is one of the main aims of therapy. In patients with HER2-positive MBC taxane-based chemotherapy in combination with dual HER2 targeted therapy with trastuzumab and pertuzumab,is the standard of care. Adverse events are well-known side effects of any cytostatic treatment and can seriously impact the patients' QoL. The synergistic combination of dual HER2-targeted therapy with trastuzumab and pertuzumab plus endocrine therapy might offer a better treatment option for these patients. First clinical trials suggest an additional benefit when a CDK4/6 inhibitor is added to the combination of endocrine therapy and anti HER2 treatment. DETECT V is a randomized phase III study comparing the safety and efficacy of trastuzumab plus pertuzumab and the CDK 4/6 inhibitor ribociclib in combination with either endocrine therapy or chemotherapy.
Trial design:
Patients with HER2 positive and hormone-receptor positive MBC are 1:1 randomized to receive trastuzumab and pertuzumab combined with endocrine therapy and ribociclib or to chemotherapy with trastuzumab and pertuzumab followed by maintenance therapy with trastuzumab, pertuzumab, endocrine therapy and ribociclib. Chemotherapy and the endocrine agents can be chosen from a variety of available regimens according to the physicians discretion.
Specific aims:
The primary objective of this study is to compare safety and tolerability in both arms, as assessed by the occurrence of AEs during the treatment period. Secondary endpoints are progression free survival, overall survival, quality-adjusted survival using the quality-adjusted time without symptoms and toxicity (Q-TWiST) method. A translational program is included investigating detection and phenotyping of circulating tumor cells (CTC)-and the assessment of marker expression on CTCs in order to validate an endocrine responsiveness score.
Present accrual and target accrual:
The DETECT V trial started 2015 in the Dept. of Gynecology, University of Ulm and at the up to 120 sites in Germany. Until June 2018 97 patients with HER2-positive, hormone-receptor positive metastatic breast cancer have been enrolled. A sample size of 270 patients is planned.
Contact information:
Jens Huober, University of Ulm, Dept of Gynecology, Breast Center, jens.huober@uniklinik-ulm.de
Sabrina Krause, University of Ulm, Dept of Gynecology, sabrina.krause@uniklinik-ulm.de
Citation Format: Krause S, Friedl T, Fehm T, Romashova T, Fasching PA, Schneeweiss A, Müller V, Taran F-A, Polasik A, Tzschaschel M, De Gregorio A, Meier-Stiegen F, Janni W, Huober J. DETECT V/CHEVENDO – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-07-01.
Collapse
Affiliation(s)
- S Krause
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - T Friedl
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - T Fehm
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - T Romashova
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - PA Fasching
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - A Schneeweiss
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - V Müller
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - F-A Taran
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - A Polasik
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - M Tzschaschel
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - A De Gregorio
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - F Meier-Stiegen
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - W Janni
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| | - J Huober
- University Hospital Ulm, Ulm, Germany; Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; University Hospital Erlangen, Erlangen, Germany; National Center for Tumor Diseases and University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Tübingen, Tübingen, Germany
| |
Collapse
|
17
|
Janni W, Rack BK, Friedl TW, Müller V, Lorenz R, Rezai M, Tesch H, Heinrich G, Andergassen U, Harbeck N, Schochter F, De Gregorio A, Tzschaschel M, Huober J, Hepp P, Fehm TN, Schneeweiss A, Lichtenegger W, Blohmer J, Hauner D, Beckmann MW, Häberle L, Fasching PA, Hauner H. Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs5-03] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Recent trials have provided evidence that obesity and a low level of physical activity are not only associated with a higher risk of developing breast cancer, but also with an increased risk for recurrence and reduced survival in breast cancer patients (pts). The SUCCESS C study is the first randomized Phase III trial to evaluate the effect of an intensive lifestyle intervention program, focusing on both physical activity and healthy diet following adjuvant chemotherapy on disease-free survival in women with early breast cancer.
Methods:
SUCCESS C is a German multicenter, 2×2 factorial design, randomized phase III study comparing disease-free survival (DFS) in pts with HER2-negative early breast cancer treated with either 3 cycles of epirubicine, fluorouracil, cyclophosphamide chemotherapy followed by 3 cycles of docetaxel (FEC-D) or 6 cycles of docetaxel-cyclophosphamide (DC). The second randomization compares DFS in pts with a body mass index (BMI) of 24—40 kg/m2 receiving either a telephone-based individualized lifestyle intervention (LI) program aiming at moderate weight loss for 2 years (LI arm) or general recommendations for a healthy lifestyle alone (non-LI arm). DFS according to lifestyle intervention was analyzed using both univariable cox regressions and multivariable cox regressions adjusted for age (years, continuous), BMI (kg/m2, continuous), menopausal status (premenopausal, postmenopausal), tumor size (pT1, pT2, pT3/pT4), nodal stage (pN0, pN1, pN2, pN3), hormone receptor status (positive, negative), grading (G1, G2, G3), histological type (ductal, lobular, other) and chemotherapy randomization (FEC-D, DC). Median follow-up was 64.2 months.
Results:
Overall, 2292 of the 3643 pts recruited for the SUCCESS C study were randomized for the lifestyle intervention program (1146 pts in both the non-LI arm and the LI arm). The Intention-to-treat analysis revealed no difference in DFS between the two treatment arms (LI vs. non-LI) in univariable analysis (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.76 — 1.28, p = 0.922) and in adjusted multivariable cox regression (HR 0.91, 95% CI 0.70 — 1.18, p = 0.48). At the 2-year follow up, pts in the LI arm lost on average 1.0 kg weight compared to the start of the LI program, while pts in the non-LI arm gained on average 0.95 kg (p < 0.001). Overall, 1477 pts completed the 2-year LI program (non-LI arm: 80.7%, 925 of 1146 pts; LI arm: 48.2%, 552 of 1146 pts; p < 0.001). Pts that completed the 2-year LI program had a significant better DFS than non-completers (HR 0.35, 95% CI 0.27 — 0.45, p < 0.001). Among completers, pts in the LI arm had a significantly better DFS than pts in the non-LI arm both in univariable analysis (HR 0.53, 95% CI 0.35 — 0.82, p = 0.004) and in adjusted multivariable cox regression (HR 0.51, 95% CI 0.33 — 0.78, p = 0.002).
Conclusions:
This explorative and non-planned interim analysis indicates that the completion of a systematic telephone life style intervention program may positively impact patient outcome in early breast cancer.
Citation Format: Janni W, Rack BK, Friedl TW, Müller V, Lorenz R, Rezai M, Tesch H, Heinrich G, Andergassen U, Harbeck N, Schochter F, De Gregorio A, Tzschaschel M, Huober J, Hepp P, Fehm TN, Schneeweiss A, Lichtenegger W, Blohmer J, Hauner D, Beckmann MW, Häberle L, Fasching PA, Hauner H. Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-03.
Collapse
Affiliation(s)
- W Janni
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - BK Rack
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - TW Friedl
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - V Müller
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - R Lorenz
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - M Rezai
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - H Tesch
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - G Heinrich
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - U Andergassen
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - N Harbeck
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - F Schochter
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - A De Gregorio
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - M Tzschaschel
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - J Huober
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - P Hepp
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - TN Fehm
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - A Schneeweiss
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - W Lichtenegger
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - J Blohmer
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - D Hauner
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - MW Beckmann
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - L Häberle
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - PA Fasching
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| | - H Hauner
- University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospit
| |
Collapse
|
18
|
Schochter F, Rack B, Fasching PA, Häberle L, Tesch H, Lorenz R, Tzschaschel M, De Gregorio A, Fehm T, Müller V, Schneeweiss A, Lichtenegger W, Beckmann MW, Scholz C, Pantel K, Janni W, Friedl TWP. Nachweis von zirkulierenden Tumorzellen bei Patientinnen mit frühem Brustkrebs fünf Jahre nach adjuvanter Chemotherapie und späte Rezidive – Ergebnisse der SUCCESS A Studie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- F Schochter
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - B Rack
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - PA Fasching
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Deutschland
| | - L Häberle
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Deutschland
| | - H Tesch
- Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Deutschland
| | - R Lorenz
- Gemeinschaftspraxis Dr. Lorenz, Hecker und Wesche, Braunschweig, Deutschland
| | | | | | - T Fehm
- Universitätsklinikum Düsseldorf, Frauenklinik, Düsseldorf, Deutschland
| | - V Müller
- Universitätsklinikum Hamburg Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Deutschland
| | - W Lichtenegger
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Deutschland
| | - MW Beckmann
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Deutschland
| | - C Scholz
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - K Pantel
- Universitätsklinikum Hamburg Eppendorf, Institut für Tumorbiologie, Hamburg, Deutschland
| | - W Janni
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - TWP Friedl
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| |
Collapse
|
19
|
Tzschaschel M, Schemm M, Polasik A, Schochter F, Ernst K, Redelstein H, Kautenburger J, Huesmann S, De Gregorio A, Friedl TW, Janni W, Huober J. Prosperus Trial – Prospektive Studie zur Evaluation des Ernährungsstatus von Patientinnen mit Mammakarzinom oder Ovarialkarzinom, die eine Chemotherapie erhalten. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
| | - M Schemm
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - A Polasik
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - F Schochter
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - K Ernst
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | | | | | - S Huesmann
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | | | - TW Friedl
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - W Janni
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - J Huober
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| |
Collapse
|
20
|
Tzschaschel M, Westernhagen U, Rack B, Schneweiss A, Müller V, Fehm T, Gade J, Lorenz R, Rezai M, Tesch H, Söling U, Polasik A, Schochter F, De Gregorio A, Mahner S, Schindlbeck C, Beckmann M, Fasching P, Janni W, Friedl TW. Gibt es einen Zusammenhang zwischen BMI und dem Nachweis von CTCs bei Patientinnen mit frühem Hochrisiko Mammakarzinom? Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
| | | | - B Rack
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - A Schneweiss
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - V Müller
- Universitätsklinikum Hamburg Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - T Fehm
- Klinikum der Heinrich-Heine-Universität, Düsseldorf, Deutschland
| | - J Gade
- Diakoniekrankenhaus Friederikenstift, Klinik für Gynäkologie, Hannover, Deutschland
| | - R Lorenz
- Gemeinschaftspraxis Dr. Lorenz, Hecker und Wesche, Braunschweig, Deutschland
| | - M Rezai
- Luisenkrankenhaus Düsseldorf, Klinik für Gynäkologie und Geburtshilfe, Düsseldorf, Deutschland
| | - H Tesch
- Onkologische Gemeinschaftspraxis, Frankfurt, Deutschland
| | - U Söling
- Gemeinschaftspraxis Siehl und Soeling, Kassel, Deutschland
| | - A Polasik
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - F Schochter
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | | | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland
| | - C Schindlbeck
- Klinikum Traunstein, Frauenklinik, Traunstein, Deutschland
| | - M Beckmann
- Friedrich-Alexander Universität Erlangen-Nürnberg, Frauenklinik, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - P Fasching
- Friedrich-Alexander Universität Erlangen-Nürnberg, Frauenklinik, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - W Janni
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| | - TW Friedl
- Universitätsfrauenklinik Ulm, Ulm, Deutschland
| |
Collapse
|
21
|
Krause S, Friedl T, Fehm T, Romashova T, Fasching P, Schneeweiss A, Müller V, Taran FA, Polasik A, Tzschaschel M, De Gregorio A, Meier-Stiegen F, Janni W, Huober J. DETECT V – Vergleich der HER2-zielgerichteten dualen Blockade plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und HR-positivem metastasiertem Mammakarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Krause
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - T Friedl
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - T Fehm
- Heinrich-Heine- Universität Düsseldorf, Frauenklinik, Düsseldorf, Deutschland
| | - T Romashova
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - P Fasching
- Universitätsklinik Erlangen, Frauenklinik, Erlangen, Deutschland
| | - A Schneeweiss
- Universitätsfrauenklinik Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - V Müller
- Universitätsfrauenklinik Hamburg-Eppendorf, Frauenklinik, Hamburg, Deutschland
| | - FA Taran
- Universitätsfrauenklinik Tübingen, Frauenklinik, Tübingen, Deutschland
| | - A Polasik
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - M Tzschaschel
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - A De Gregorio
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - F Meier-Stiegen
- Heinrich-Heine- Universität Düsseldorf, Frauenklinik, Düsseldorf, Deutschland
| | - W Janni
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| | - J Huober
- Universitätsklinikum Ulm, Frauenklinik, Ulm, Deutschland
| |
Collapse
|
22
|
De Gregorio A, De Gregorio N, Friedl TWP, Scholz C, Reister F, Janni W, Ebner F. Postpartale Notfallhysterektomie – Analyse einer Fallserie der letzten 13 Jahre an einem Level I Perinatalzentrum. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1660636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
| | | | | | | | | | - W Janni
- Universitätsfrauenklinik Ulm
| | - F Ebner
- Klinik für Frauenheilkunde HELIOS Amper Klinik Dachau
| |
Collapse
|
23
|
De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol 2018; 12:773-782. [PMID: 29750009 PMCID: PMC5933334 DOI: 10.2147/opth.s146919] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The recent development of new devices that are significantly less invasive, collectively termed minimally invasive glaucoma surgery, offers new perspective of intraocular pressure reduction with less risk, short operating times, and rapid recovery. The aim of this work is to provide a panoramic review of the currently published clinical data to assess the potential role of XEN gel stent (Allergan PLC, Irvine, CA, USA) in the management of glaucoma, which is the only filtering minimally invasive glaucoma surgery device that allows the subconjunctival filtration. The ab interno placement of the XEN gel stent offers an alternative for lowering intraocular pressure in refractory glaucoma as a final step, and in patients intolerant to medical therapy as an early surgical approach with minimum conjunctival tissue disruption, restricted flow to avoid hypotony, and long-term safety.
Collapse
Affiliation(s)
- A De Gregorio
- Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy
| | - E Pedrotti
- Eye Clinic, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - G Stevan
- Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy
| | - A Bertoncello
- Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy
| | - S Morselli
- Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy
| |
Collapse
|
24
|
|
25
|
Vitale M, Masulli M, Cocozza S, Anichini R, Babini AC, Boemi M, Bonora E, Buzzetti R, Carpinteri R, Caselli C, Ceccarelli E, Cignarelli M, Citro G, Clemente G, Consoli A, Corsi L, De Gregorio A, Di Bartolo P, Di Cianni G, Fontana L, Garofolo M, Giorda CB, Giordano C, Grioni S, Iovine C, Longhitano S, Mancastroppa G, Mazzucchelli C, Montani V, Mori M, Perriello G, Rinaldi ME, Ruffo MC, Salvi L, Sartore G, Scaranna C, Tonutti L, Zamboni C, Zogheri A, Krogh V, Cappellini F, Signorini S, Riccardi G, Vaccaro O. Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes - The TOSCA.IT study. Nutr Metab Cardiovasc Dis 2016; 26:879-885. [PMID: 27212622 DOI: 10.1016/j.numecd.2016.04.006] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Revised: 02/08/2016] [Accepted: 04/01/2016] [Indexed: 11/21/2022]
Abstract
BACKGROUND AND AIMS Diabetic women have a more adverse plasma lipid profile than men. Sex differences in dietary habits may play a role, but are little investigated. The study evaluates the quality of diet, adherence to the nutritional recommendations of the Diabetes and Nutrition Study Group and their relation with plasma lipid in men and women with diabetes. METHODS AND RESULTS We studied 2573 people, aged 50-75, enrolled in the TOSCA.IT study (clinicaltrials.gov; NCT00700856). Plasma lipids were measured centrally. Diet was assessed with a semi-quantitative food frequency questionnaire. Women had a more adverse plasma lipid profile than men. Women consumed significantly more legumes, vegetables, fruits, eggs, milk, vegetable oils, and added sugar, whereas men consumed more starchy foods, soft drinks and alcoholic beverages. This stands for a higher proportion (%) of energy intake from saturated fat and added sugar (12.0 ± 2.4 vs 11.5 ± 2.5 and 3.4 ± 3.2 vs 2.3 ± 3.2, P < 0.04), and a higher intake of fiber (11.2 ± 2.8 vs 10.4 ± 2.6 g/1000 Kcal/day) in women. Adherence to the recommendations for saturated fat and fiber consumption was associated with significantly lower LDL-cholesterol regardless of sex. Adherence to the recommendations for added sugars was associated with significantly lower triglycerides and higher HDL-cholesterol in men and women. CONCLUSIONS Men and women with diabetes show significant differences in adherence to nutritional recommendations, but sex differences in plasma lipid profile are unlikely to be explained by nutritional factors. Adherence to the nutritional recommendations is associated with a better plasma lipid profile regardless of sex, thus reinforcing the importance of substituting saturated for unsaturated fat sources, increasing fiber and reducing added sugar intake.
Collapse
Affiliation(s)
- M Vitale
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - M Masulli
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - S Cocozza
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - R Anichini
- UO di Diabetologia, USL 3, Pistoia, Italy
| | - A C Babini
- Diabetologia, Ospedale Infermi, Rimini, Italy
| | - M Boemi
- UOC Malattie Metaboliche e Diabetologia, Istituto INRCA-IRCCS, Ancona, Italy
| | - E Bonora
- Dipartimento di Medicina, Divisione di Endocrinologia, Diabete e Metabolismo, Università di Verona, Italy
| | - R Buzzetti
- UOC di Diabetologia Universitaria, Ospedale Santa Maria Goretti, Latina, Italy
| | - R Carpinteri
- UO di Malattie Metaboliche e Diabetologia, AO Treviglio, Italy
| | - C Caselli
- UOD Endocrinologia e Diabetologia, AUSL della Romagna, Cesena, Italy
| | - E Ceccarelli
- UOC Diabetologia, Dipartimento di Medicina, Chirurgia e Neuroscienze, Università di Siena, Italy
| | | | - G Citro
- UO Endocrinologia e Diabetologia, ASP, Potenza, Italy
| | - G Clemente
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - A Consoli
- DMSI e CeSI-Met, Università di Chieti-Pescara, Italy
| | - L Corsi
- SSD Diabetologia e Malattie Metaboliche, ASL 4 Chiavarese, Genova, Italy
| | - A De Gregorio
- UOSD Diabetologia, Ospedale San Salvatore, L'Aquila, Italy
| | - P Di Bartolo
- UO di Diabetologia Ravenna, A. Usl Romagna, Italy
| | | | - L Fontana
- UOC Diabetologia e Dietologia, Ospedale S. Pertini, Roma, Italy
| | - M Garofolo
- Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy
| | | | - C Giordano
- Endocrinologia e Malattie Metaboliche, Università di Palermo, Italy
| | - S Grioni
- Unità di Epidemiologia e Prevenzione, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy
| | - C Iovine
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - S Longhitano
- Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Italy
| | - G Mancastroppa
- Dipartimento di Medicina Clinica e Sperimentale, Università di Parma, Italy
| | | | - V Montani
- UOSD, Presidio Ospedaliero di Atri, Italy
| | - M Mori
- SSD Diabetologia, ASL 1, Massa Carrara, Italy
| | | | - M E Rinaldi
- Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma "Tor Vergata", Italy
| | - M C Ruffo
- Dipartimento di Medicina Interna, Policlinico di Messina, Italy
| | - L Salvi
- Dipartimento di Medicina Clinica e Molecolare, Università "La Sapienza", Roma, Italy
| | - G Sartore
- DPT Medicina, Università degli Studi di Padova, Italy
| | - C Scaranna
- USC Malattie Endocrine e Diabetologia, AO Papa Giovanni XXIII, Bergamo, Italy
| | - L Tonutti
- SOC di Endocrinologia e Malattie del Metabolismo, AOU S. Maria della Misericordia, Udine, Italy
| | - C Zamboni
- UO Malattie Metaboliche, Dietologia e Nutrizione Clinica, AOU Arcispedale S. Anna, Ferrara, Italy
| | - A Zogheri
- UO di Diabetologia, Ospedale di Prato, Italy
| | - V Krogh
- Unità di Epidemiologia e Prevenzione, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy
| | - F Cappellini
- Dipartimento di Patologia Sperimentale, Ospedale di Desio, Università di Milano Bicocca, Italy
| | - S Signorini
- Dipartimento di Patologia Sperimentale, Ospedale di Desio, Università di Milano Bicocca, Italy
| | - G Riccardi
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy
| | - O Vaccaro
- Dipartimento di Medicina Clinica e Chirurgia, Università "Federico II" di Napoli, Italy.
| |
Collapse
|
26
|
Abstract
In this paper telegraph processes on geodesic lines of the Poincaré half-space and Poincaré disk are introduced and the behavior of their hyperbolic distances examined. Explicit distributions of the processes are obtained and the related governing equations derived. By means of the processes on geodesic lines, planar random motions (with independent components) in the Poincaré half-space and disk are defined and their hyperbolic random distances studied. The limiting case of one-dimensional and planar motions together with their hyperbolic distances is discussed with the aim of establishing connections with the well-known stochastic representations of hyperbolic Brownian motion. Extensions of motions with finite velocity to the three-dimensional space are also hinted at, in the final section.
Collapse
|
27
|
D'Andrea S, Giordano AV, Carducci S, Sacchetti L, Necozione S, Costanzo M, De Gregorio A, Micillo A, Francavilla F, Francavilla S, Barbonetti A. Embolization of left spermatic vein in non-obstructive azoospermic men with varicocele: role of FSH to predict the appearance of ejaculated spermatozoa after treatment. J Endocrinol Invest 2015; 38:785-90. [PMID: 25740066 DOI: 10.1007/s40618-015-0259-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 02/09/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE Varicocele repair in non-obstructive azoospermia (NOA) was occasionally associated to ejaculated spermatozoa independently from clinical and laboratory measures. We performed a prospective study in infertile men affected by NOA and left side varicocele to find whether or not the appearance of ejaculated spermatozoa after varicocele repair is predicted by baseline measures. METHODS Patients with NOA and grade II, or grade III left side varicocele were submitted to hormone analysis and to scrotal color Doppler ultrasound (CDU). Azoospermia was confirmed in 23 patients aged 25-47 years who were than submitted to varicocele repair through a retrograde internal spermatic vein embolization. Patients were re-evaluated after 6 months. RESULTS Six months after varicocele repair 12 patients (52.2 %) were still azoospermic (Group 1) while 11 patients (47.8 %) reported ejaculated spermatozoa (Group 2) [sperm count: 1.3 × 10(6)/mL; 0.5 × 10(6)/mL-1.6 × 10(6)/mL (median 25th-75th centiles)]. Serum baseline FSH was lower in Group 2 compared to Group 1 (p = 0.012), while no differences between groups were revealed for all other clinical and laboratory parameters. ROC analysis indicated that baseline FSH level predicted the appearance of ejaculated spermatozoa after treatment [AUC = 0.811; 95 % Confidence Interval (CI) 0.6-0.9; p = 0.0029]. A cut-off level of FSH <10.06 mIU/mL identified 82.0 % of cases with ejaculated spermatozoa with a specificity of 81.8 % and a sensitivity of 83.3 %. CONCLUSION Selected patients with NOA may show ejaculated spermatozoa after a non-invasive repair of a left side varicocele, therefore avoiding testicular sperm extraction. Baseline serum FSH was a valuable predictor for ejaculated spermatozoa after treatment.
Collapse
Affiliation(s)
- S D'Andrea
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| | - A V Giordano
- Interventional Radiology Unit, University Hospital San Salvatore, L'Aquila, Italy
| | - S Carducci
- Interventional Radiology Unit, University Hospital San Salvatore, L'Aquila, Italy
| | - L Sacchetti
- Interventional Radiology Unit, University Hospital San Salvatore, L'Aquila, Italy
| | - S Necozione
- Department of Epidemiology, University of L'Aquila, L'Aquila, Italy
| | - M Costanzo
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| | - A De Gregorio
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| | - A Micillo
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| | - F Francavilla
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| | - S Francavilla
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
| | - A Barbonetti
- Department of Life, Health and Environment Sciences, Andrology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy
| |
Collapse
|
28
|
Russo S, Russo F, Maiello FM, Paolini B, Carrabba A, De Gregorio A. Biphasic large cell neuroendocrine carcinoma--pure mucinous carcinoma of the gallbladder (MANEC): a unique combination. Pathologica 2012; 104:185-189. [PMID: 23316622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
INTRODUCTION We report a case of primary combined large cell neuroendocrine carcinoma (LCNEC)--pure mucinous carcinoma of the gallbladder (MANEC)--which represents the first description of this entity. METHODS The patient is a 59-year-old Italian male who underwent cholecystectomy under a preoperative diagnosis of cholecystitis with gallstones and gallbladder tumour. During laparotomy, cholecystectomy, liver wedge resection and regional lymph node dissection were performed. The resected gallbladder showed a thickened wall, gallstones and a 4 cm gelatinous, cauliflower-like soft tissue mass. RESULTS Following surgery, the gallbladder tumour was diagnosed as a mixed endocrine-exocrine carcinoma. There was evidence of lymph node metastasis or direct liver invasion. The mucin-producing carcinoma was composed of poorly differentiated glandular cells with mucin lakes. The LCNEC was characterized by large cells with prominent nucleoli, coarse chromatin and a high mitotic rate. The cells showed an "organoid" growth pattern with rosette formation and frequent areas of necrosis. Chromogranin A, synaptophysin and CD56 were diffusely and strongly expressed. DISCUSSION This case may provide helpful insights regarding the histogenesis of this unusual combination of tumors: the concept of a collision tumor between two neoplasms that have arisen in adjacent areas may be the best explanation for its pathogenesis.
Collapse
MESH Headings
- Adenocarcinoma, Mucinous/complications
- Adenocarcinoma, Mucinous/pathology
- Adenocarcinoma, Mucinous/surgery
- Carcinoma, Large Cell/complications
- Carcinoma, Large Cell/pathology
- Carcinoma, Large Cell/surgery
- Carcinoma, Neuroendocrine/complications
- Carcinoma, Neuroendocrine/pathology
- Carcinoma, Neuroendocrine/surgery
- Cholecystectomy
- Cholelithiasis/complications
- Cholelithiasis/pathology
- Cholelithiasis/surgery
- Gallbladder Neoplasms/complications
- Gallbladder Neoplasms/pathology
- Gallbladder Neoplasms/surgery
- Humans
- Male
- Middle Aged
- Neoplasms, Multiple Primary/complications
- Neoplasms, Multiple Primary/pathology
- Neoplasms, Multiple Primary/surgery
Collapse
Affiliation(s)
- S Russo
- Pathology Dpt., Maresca Hospital, Torre del Greco, Napoli, Italy.
| | | | | | | | | | | |
Collapse
|
29
|
Ciabattoni A, Drago S, Grassi G, De Gregorio A, Felicioni F, Petrucci A, Consorti R, Mirri M. PD-0216 LONG TERM RESULTS OF A RANDOMIZED STUDY OF IORT VERSUS EXTERNAL BEAM BOOST IN EARLY BREAST CANCER PATIENTS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70555-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Zottola T, Briganti P, Cuoco E, D’Amici L, De Gregorio A, Guzzon L, Manocchio A, Mancuso M, Condoleo RU. STUDY OF THE MICROBIOLOGICAL HAZARDS IN THE PRODUTION OF THE MOZZARELLA BUFFALO CHEESE. Ital J Food Saf 2009. [DOI: 10.4081/ijfs.2008.4.39] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
31
|
|
32
|
De Gregorio A, Mandalari G, Arena N, Nucita F, Tripodo MM, Lo Curto RB. SCP and crude pectinase production by slurry-state fermentation of lemon pulps. Bioresour Technol 2002; 83:89-94. [PMID: 12056496 DOI: 10.1016/s0960-8524(01)00209-7] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Single cell protein (SCP) and crude pectinolytic enzymes production from citrus pulps is reported. SCP and enzymes were produced by slurry-state flask cultivation of Aspergillus niger and Trichoderma viride on pulps from lemon juice clarification. Production as well as crude pectinase activity was not affected by the high dry matter content of the pulps. Both the protein content in the residue and the enzyme activity in the supernatant were higher in T. viride than in A. niger culture. The crude pectinase of T. viride, whose specific activity was similar to that found for a commercial concentrated preparation, could be utilized in the same citrus processing factory as well as in other factories which use large amounts of pectinolytic crude preparations, for example to enhance depuration plant performance.
Collapse
Affiliation(s)
- A De Gregorio
- Department of Organic and Biological Chemistry, University of Messina, S. Agata, Italy
| | | | | | | | | | | |
Collapse
|
33
|
Nina P, Franco A, Barbato R, De Gregorio A, Schisano G. Extradural low cervical chordoma. Case report. J Neurosurg Sci 1999; 43:305-9. [PMID: 10864394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Chordoma of the mobile segments of the spine are infrequent lesions and especially rare are those located in the lower part of the cervical spine. We present the case of a cervical chordoma located in the C6 vertebral body diagnosed by means of magnetic resonance imaging and operated on by an anterior approach. The authors discuss the clinical and neuroradiological features of this disease also analysing some controversial therapeutic aspects.
Collapse
Affiliation(s)
- P Nina
- Department of Neurosurgery, Nuovo Pellegrini Hospital, Naples.
| | | | | | | | | |
Collapse
|
34
|
De Gregorio A, Risitano A, Capo C, Criniò C, Petruzzelli R, Desideri A. Evidence of carbamoylphosphate induced conformational changes upon binding to human ornithine carbamoyltransferase. Biochem Mol Biol Int 1999; 47:965-70. [PMID: 10410242 DOI: 10.1080/15216549900202083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Human liver ornithine carbamoyltransferase undergoes absorbance changes in the UV region upon formation of the carbamoylphosphate-norvaline-enzyme ternary complex. The UV changes are similar in the presence of carbamoylphosphate alone, whilst they are lower in the presence of ornithine or norvaline alone. The extent of the UV changes correlates with the enzyme susceptibility to proteolytic degradation. The free native enzyme is completely and rapidly hydrolyzed by trypsin, whilst it is partially protected upon carbamoylphosphate binding. The extent of protection increases for the carbamoylphosphate-norvaline-enzyme ternary complex. These results strongly suggest that the binding of the first substrate, i.e. carbamoylphosphate, to human ornithine carbamoyltransferase induces a large protein isomerization, which regards the polar domain plus a part of equatorial domain of each subunit.
Collapse
Affiliation(s)
- A De Gregorio
- Dipartimento di Chimica Organica e Biologica, Università di Messina, Italy.
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
A quantitative ultraviolet detection method for determining ornithine transcarbamylase (OTC-ase) activity using micellar electrokinetic chromatography (MEKC) is described. The method is based on the direct determination of citrulline formed upon enzymatic reaction. Using a background electrolyte consisting of 35 mM sodium tetraborate, pH 9.3, containing 65 mM sodium dodecyl sulfate (SDS), the peak of citrulline in the electropherogram was easily identified and integrated. This allowed us to determine the rate of formation of the reaction product and to calculate the kinetic parameter Km of the OTC-ase investigated. The capillary electrophoretic method developed was applied to the determination of OTC-ase activity in plasma samples for citrulline in the nanogram range.
Collapse
Affiliation(s)
- S Viglio
- Dipartimento di Biochimica A. Castellani, Università di Pavia, Italy
| | | | | | | | | | | |
Collapse
|
36
|
Barbera M, De Gregorio A, Panarisi S, Paola Q, Cammarata C, Solazzo G, Curto F, Curto G. Dynamic ultrasound for assessing obstructions in the upper urinary tracts: Usefulness and reliability. Urologia 1998. [DOI: 10.1177/039156039806500110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Renal ultrasound is not a functional type of examination, which means it cannot be used to determine the degree of obstruction of the upper urinary tract, for which more or less invasive exams such as Whitaker's test, renogram and/or urography must be perfomed. Dynamic ultrasound with furosemide test gives information on the morphology and also the degree of obstruction and is extremely useful in the pre and post-operative assessment of patients with upper urinary tract pathologies. A total of 72 renoureteral units in 39 patients were studied. Patients with a normal “dynamic” ultrasound picture were excluded, while the others were also studied with renogram and/or urography. Data analysis shows dynamics ultrasound reliability is on a par with that of the above-mentioned invasive methods (88–95%). Given the simplicity of use and its availability in all hospital structures, it is therefore considered that dynamic ultrasound should be used immediately in studying obstructions of the upper urinary tracts.
Collapse
Affiliation(s)
| | - A. De Gregorio
- Unità Operativa di Nefrologia - Azienda Ospedaliera “Ospedali Civili Riuniti” - Sciacca (Agrigento)
| | | | | | | | | | | | | |
Collapse
|
37
|
Lambiase A, Centofanti M, Micera A, Manni GL, Mattei E, De Gregorio A, de Feo G, Bucci MG, Aloe L. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol 1997; 235:780-5. [PMID: 9439971 DOI: 10.1007/bf02332863] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND It has been shown that intravitreal injection of NGF inhibits ganglion cell degeneration after optic nerve transection and ischemic injury. The aim of our study was to investigate the presence of NGF in aqueous humor and its involvement in retinal damage during ocular hypertension. METHODS We used an experimental model of ocular hypertension in rabbit. Before treatment and 4, 10 and 15 days after induction of hypertension, we evaluated histological retinal damage and NGF levels in aqueous humor using an immunoenzymatic assay. Polyclonal anti-NGF antibodies were injected intravitreally into one eye of each rabbit (n = 6), and the animals were killed after 4 days of hypertension. Another group of rabbits (n = 12) was injected retro-ocularly with NGF and killed after 10 or 15 days of treatment for histologic evaluation of the retina. RESULTS Our data show that experimental ocular hypertension in adult rabbits induces retinal damage and enhances local NGF levels. The highest NGF value was found after 4 days of intraocular hypertension: high levels persisted, though to a lesser extent, for up to 15 days. Histological examination revealed that the number of retinal ganglion cells (RGC) remained unchanged during the first 4 days but decreased at 10 days. These studies also showed that retro-ocular administration of NGF reduced RGC loss, whereas intraocular injection of NGF antibodies, which inhibited the endogenous NGF, exacerbated the retinal insult. CONCLUSION These findings demonstrate a protective effect of NGF on RGC damaged by ocular hypertension and prompt further investigations to evaluate a possible therapeutic use of NGF to retard RGC death in humans.
Collapse
Affiliation(s)
- A Lambiase
- CNR, Institute of Neurobiology, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ammaturo C, Morra C, D'Eliso E, Giardiello C, Vecchio G, De Gregorio A, Maiello FM, Trinchese G. [Leiomyosarcoma of the small intestine and the colorectum. A case contribution]. MINERVA CHIR 1996; 51:645-51. [PMID: 9082227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Smooth muscle tumors of the alimentary tract are uncommon. A retrospective study was made of 7 patients treated for leiomyosarcoma of the small and large bowel to identify prognostic factors that influence results. The symptoms associated with these tumors varied according to the anatomic sites of the lesions and the position of the growth in relation to the intestinal lumen but the most common presenting clinical signs are bleeding or obstruction. The differential diagnosis between benign and malignant smooth muscle tumors is sometimes quite difficult. Clinical behavior of the myosarcomas of the gastrointestinal tract can be predicted to a large extent by the site of the tumor, the presence or absence of invasion of adjacent vital organs, and the histopathologic grade of malignancy. Although the mitotic activity of a gastrointestinal stromal tumor remains the most critical prognostic factor, tumors have been seen to recur locally and to metastasize even with rare or absent mitotic figures. Further studies are needed to pinpoint the factors that may be correlated to the prognosis.
Collapse
Affiliation(s)
- C Ammaturo
- Divisione di Chirurgia d'Urgenza, ASL No 44, Opsedale Loreto Mare, Napoli
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Manni G, Lambiase A, Centofanti M, Mattei E, De Gregorio A, Aloe L, de Feo G. Histopathological evaluation of retinal damage during intraocular hypertension in rabbit: involvement of ganglion cells and nerve fiber layer. Graefes Arch Clin Exp Ophthalmol 1996; 234 Suppl 1:S209-13. [PMID: 8871176 DOI: 10.1007/bf02343074] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Current clinical tests do not detect glaucomatous signs until the onset of substantial retinal damage. Therefore animal models are required to investigate the very early histopathological alterations in glaucoma disease. We used an experimental model of intraocular hypertension to compare early changes in retinal ganglion cell (RGC) density with the thickness of the nerve fiber layer (NFL). METHODS Methylcellulose 2% was injected into the anterior chamber of 18 eyes of 18 New Zealand albino rabbits. Intraocular pressure was measured 6 h after the injection and thenceforth once a day using a Shiötz tonometer. Histopathological analysis was performed on days 4, 10, and 15 following the induction of hypertension (six eyes for each group). Sections from the upper temporal retina were stained with hematoxylin-eosin and immunohistochemically using a polyclonal antibody PGP 9.5 to identify RGC. An image analysis system was used to evaluate the RGC and the thickness of the NFL. RESULTS We observed a significant increase in intraocular pressure until the end of the experiment. Histological analysis showed, after 10 days of ocular hypertension, a significant decrease in RGC density (P < 0.05) and a significant increase (P < 0.05) in glial cell density. We found a significant correlation between RGC loss and cell area at 4 days (P < 0.01; Cc = 0.86) and at 10 days (P < 0.002; Cc = 0.91) of intraocular hypertension. We did not observe a significant decrease in the NFL thickness until 10 days of intraocular hypertension. CONCLUSIONS Our study confirms the size-dependent RGC loss during intraocular hypertension and shows no early decrease in NFL thickness.
Collapse
Affiliation(s)
- G Manni
- Department of Ophthalmology, University of Rome, Tor Vergata, Italy
| | | | | | | | | | | | | |
Collapse
|
40
|
Valentini G, De Gregorio A, Di Salvo C, Grimm R, Bellocco E, Cuzzocrea G, Iadarola P. An essential lysine in the substrate-binding site of ornithine carbamoyltransferase. Eur J Biochem 1996; 239:397-402. [PMID: 8706746 DOI: 10.1111/j.1432-1033.1996.0397u.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Treatment of ornithine carbamoyltransferase from dolphin Stenella with pyridoxal phosphate, followed by reduction with NaBH4 resulted in complete loss of enzyme activity. The phosphate alone or the substrate analogue 2-aminovaleric acid moderately decreased the extent of inactivation, while carbamoyl phosphate plus 2-aminovaleric acid provided complete protection from inactivation. The partially inactivated enzyme showed K(m) values for substrates equivalent to those of native enzyme and lowered Kcat values. Two lysyl residues were substantially modified in the absence of ligands but only one of them was responsible for the inactivation of catalytic activity. Modification of a single subunit was sufficient to completely abolish the catalytic activity of the trimeric enzyme. The lysine involved has been identified as lysine 56 on the known primary structure of homologous human liver enzyme.
Collapse
Affiliation(s)
- G Valentini
- Dipartimento di Biochimica, Università di Pavia, Italy
| | | | | | | | | | | | | |
Collapse
|
41
|
De Gregorio A, Valentini G, Bellocco E, Desideri A, Cuzzocrea G. A comparative study on liver ornithine carbamoyl transferase from a marine mammal Stenella and an elasmobranch Sphyrna zygaena. Comp Biochem Physiol B 1993; 105:497-501. [PMID: 8365105 DOI: 10.1016/0305-0491(93)90079-k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
1. Ornithine carbamoyl transferases from liver of the dolphin Stenella and the shark Sphyrna zygaena were purified to homogenity and compared for some kinetic and structural properties. 2. The two enzymes showed a specific activity of 211 and 115 respectively. 3. With respect to molecular weight, trimeric subunit structure and Km values, they were alike and similar to enzymes from other species. 4. Both enzymes were thermolable, but they were protected from thermal inactivation in a different way by ornithine and phosphate. 5. The two enzymes focused, respectively, at pH 8.6 and between pH 6.4 and 8.0, the former value being appreciably higher than those of enzymes from other species.
Collapse
Affiliation(s)
- A De Gregorio
- Department of Organic and Biological Chemistry, University of Messina, Italy
| | | | | | | | | |
Collapse
|
42
|
Bellocco E, Leuzzi U, De Gregorio A, Laganà G, Risitano A, Desideri A, Cuzzocrea G. Partial purification and properties of ornithine carbamoyltransferase from Citrus limonum leaves. Biochem Mol Biol Int 1993; 29:281-9. [PMID: 8495212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Ornithine carbamoyltransferase (carbamoylphosphate: L-ornithine carbamoyltransferase, EC 2.1.3.3) has been partially purified from C.limonum leaves. The data indicate the presence of only the anabolic enzyme. The activity is strongly influenced by pH, ionic strength and ornithine concentration. Optimal activity for the enzyme dissolved in the tri-buffer: diethanolamine,2-(N-morpholino) ethanesulfonic acid, N-ethylenmorpholine (0.051 M/0.1 M/0.051 M) is at pH 9.0, when ornithine is 10 mM. The enzyme catalyses an ordered-sequential process in which carbamoyl phosphate binds first followed by L-ornithine and then L-citrulline leaves followed by phosphate. Support for this statement comes from product inhibition and evidence of abortive ternary complex formation.
Collapse
Affiliation(s)
- E Bellocco
- Department of Organic and Biological Chemistry, University of Messina Salita Sperone
| | | | | | | | | | | | | |
Collapse
|
43
|
Ministeri CM, Mucaria A, Bennici S, Visconti G, Calabrese S, De Gregorio A. [Uremic neuropathy. Clinical and neurophysiological data on patients on chronic hemodialysis treatment]. Clin Ter 1986; 118:89-92. [PMID: 3742981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
44
|
Marin J, Salaices M, De Gregorio A. Effect of some vasodilators on cat femoral arteries. J Pharm Pharmacol 1986; 38:146-9. [PMID: 2420963 DOI: 10.1111/j.2042-7158.1986.tb04532.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Adenosine, cyclic-AMP (cAMP), papaverine and 1-methyl-3-isobutylxanthine (MIX) evoked dose-dependent vasodilatation in cat femoral arteries precontracted with 75 mM K+. The vasodilator response induced at maximal concentration used was: papaverine greater than MIX greater than adenosine = cAMP. With regard to the potency of relaxant effects (IC10) the order was MIX = cAMP = papaverine greater than adenosine. The dilatation elicited by papaverine, adenosine and cAMP was increased by MIX. Preincubation with adenosine enhanced the relaxation induced by MIX and reduced that produced by cAMP. These results indicate that the effects of adenosine and cAMP seem not to be mediated by specific surface receptors but by a cAMP-dependent mechanism. The interference between adenosine and cAMP could be due to competition for a similar site and/or mechanism.
Collapse
|
45
|
De Gregorio A, Esposito C, Coscia Porrazzi L, De Falco ML. [Urinary cytology in the diagnosis of urothelial neoplasms (one year of experience in the St. Leonardo Hospital of Castellamare di Stabia)]. Pathologica 1979; 71:829-33. [PMID: 262297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
46
|
De Gregorio A, Esposito C, Quartu F, De Falco ML. [Preliminary data (31 cases) on the cyto-histological and clinical correlates in papillary neoplasms of the urothelium]. Pathologica 1979; 71:835-43. [PMID: 262298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
47
|
Falconi C, Coscia Porrazzi L, Mondola P, Santangelo F, De Gregorio A, De Rosa M, Gambacorta A. [Lipid content of aorta, spleen and kidneys in rats on a high fat diet and treated with a chromatographic thymus gland fraction]. Boll Soc Ital Biol Sper 1978; 54:2369-77. [PMID: 756731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A chromatographic fraction obtained from a thymus homogenate of young calf, was administered by intraperitoneal means to a distinct group of rats previously fed on a diet with high content of dietary fat for 50 days. The serum values of cholesterol and triglycerides and of total lipids in spleen, kidneys and aorta which were obtained from these animals were compared with those of rats fed on the same diet and not injected with the thymus fraction. The considerable decrease of the seric values was not followed by conparable results of the lipidic content in the organs.
Collapse
|
48
|
Porrazzi LC, Quarto F, De Gregorio A. Malignant Lymphoma, Burkitt's Type: Histologic Report of Two Cases in Italy. Tumori 1978; 64:645-8. [PMID: 741524 DOI: 10.1177/030089167806400612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Two cases of undifferentiated Burkitt's type malignant lymphoma with prevalent ovarian localization and observed in Italy are described histologically. Some brief considerations about the extra African diffusion of this lymphoma are pointed out.
Collapse
|